Company Profile
Sonoma Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- SNOA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.13 USD (-5.83%)
Close
Last updated: August 5, 2026
4.03M USD
Market cap
Why the stock is moving
The latest monitored company update is “Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA.” The corresponding closing-price reaction is not yet available.
Company overview
Hypochlorous Acid Medical Products
Sonoma Pharmaceuticals develops and manufactures stabilized hypochlorous acid products for wound care, eye care, nasal care, oral care, dermatology, podiatry, animal health, and non-toxic disinfection.
Microcyn Technology
The company’s Microcyn technology produces safe and stable HOCl formulations. The products are intended to reduce itching, pain, scarring, and irritation without damaging healthy tissue and are used in applications including minor abrasions, cuts, and intact-skin management.
Broad End-Market Portfolio
Sonoma adapts the same stabilized HOCl technology across human and animal healthcare. This creates a product portfolio serving wound care, dermatology, eye and nasal care, oral care, podiatry, animal health, and non-toxic disinfection.
Global Commercial Network
Sonoma products are sold directly or through partners in more than 55 countries. The company has recently expanded its U.S. product lineup and channel relationships, including the manufacture of a new HOCl wound cleanser for Medline.
Future catalysts
Sonoma’s catalysts are wound-care and skin-health product demand, along with any update that clarifies the commercial path. The business moves on product adoption.
Recent news
- 01
- 02
- 03
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
Source: Sonoma Pharmaceuticals
- 04
Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering
Source: Sonoma Pharmaceuticals
- 05
Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart
Source: Sonoma Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Sonoma Pharmaceuticals (SNOA)?
Sonoma Pharmaceuticals (SNOA) most recently closed at 1.13 USD, a -5.83% move versus the previous session.
What is the market cap of Sonoma Pharmaceuticals (SNOA)?
Sonoma Pharmaceuticals currently has a market capitalization of 4.03M USD on BioPharmSignal.
What does Sonoma Pharmaceuticals do?
Hypochlorous Acid Medical Products Sonoma Pharmaceuticals develops and manufactures stabilized hypochlorous acid products for wound care, eye care, nasal care, oral care, dermatology, podiatry, animal health, and non-toxic disinfection. Microcyn Technology The company’s Microcyn technology produces safe and stable HOCl formulations. The products are...
On which exchange is SNOA stock listed?
Sonoma Pharmaceuticals (SNOA) is associated with NASDAQ, United States, Biopharma.
What is Hypochlorous?
Hypochlorous Acid Medical Products Sonoma Pharmaceuticals develops and manufactures stabilized hypochlorous acid products for wound care, eye care, nasal care, oral care, dermatology, podiatry, animal health, and non-toxic disinfection.
Which conditions is Sonoma Pharmaceuticals targeting with Hypochlorous?
Sonoma Pharmaceuticals is associated with dermatology based on its company overview and current catalyst commentary.
How does Sonoma Pharmaceuticals describe recent progress with Hypochlorous?
Sonoma’s catalysts are wound-care and skin-health product demand, along with any update that clarifies the commercial path. The business moves on product adoption.
What is Acid?
Hypochlorous Acid Medical Products Sonoma Pharmaceuticals develops and manufactures stabilized hypochlorous acid products for wound care, eye care, nasal care, oral care, dermatology, podiatry, animal health, and non-toxic disinfection.